Comparative Pharmacology
Head-to-head clinical analysis: APALUTAMIDE versus NUBEQA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APALUTAMIDE versus NUBEQA.
APALUTAMIDE vs NUBEQA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
240 mg orally once daily with or without food.
600 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3 days (72 hours) for apalutamide and 3–5 days for the active metabolite N-desmethyl-apalutamide. The long half-life supports once-daily dosing and requires approximately 2–3 weeks to reach steady state.
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
Apalutamide and its active metabolite N-desmethyl-apalutamide are eliminated primarily via hepatic metabolism and subsequent fecal excretion. Approximately 65% of the dose is recovered in feces (as unchanged drug and metabolites) and 24% in urine (primarily as metabolites). Renal excretion of unchanged drug is negligible.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
Category C
Category C
Androgen Receptor Inhibitor
Androgen Receptor Inhibitor